Novel pediatric delivery systems for second-line anti-tuberculosis medications: a case study.
J Furin, G Brigden, E Lessem, M C Becerra
Index: Int. J. Tuberc. Lung Dis. 17(9) , 1239-41, (2013)
Full Text: HTML
Abstract
Tens of thousands of children are sick with multidrug-resistant forms of tuberculosis (MDR-TB), but there are limited child-friendly delivery systems for second-line medications. This case study presents the development of a granular dosing spoon pediatric delivery system for para-aminosalicylic acid. This product is the first of its kind for MDR-TB and could serve as a model for the development of other urgently needed pediatric delivery systems for second-line anti-tuberculosis drugs.
Related Compounds
Related Articles:
2015-02-09
[ChemBioChem. 16(3) , 424-31, (2015)]
Therapeutic antibodies reveal Notch control of transdifferentiation in the adult lung.
2015-12-03
[Nature 528 , 127-31, (2015)]
2015-01-01
[J. Pharm. Biomed. Anal. 102 , 9-16, (2014)]
2014-12-01
[Invest. Ophthalmol. Vis. Sci. 55(12) , 8111-22, (2014)]
2015-06-01
[J. Enzyme Inhib. Med. Chem. 30 , 420-9, (2015)]